Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine-18-DCFPyL - Progenics Pharmaceuticals

Drug Profile

Fluorine-18-DCFPyL - Progenics Pharmaceuticals

Alternative Names: [18F]DCFPyL; DCFPyL-18F; PyL™

Latest Information Update: 26 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer National Cancer Institute (USA); Northwestern University; Progenics Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Wisconsin-Madison
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Gynaecological cancer
  • Phase I Neurilemmoma

Most Recent Events

  • 23 Dec 2019 Progenics intends to submit a NDA with the US FDA in the second half of 2020
  • 23 Dec 2019 Efficacy and adverse events data from the phase-III CONDOR trial in Prostate cancer (Diagnosis) released by Progenics Pharmaceuticals
  • 05 Aug 2019 Prpgenics Pharmaceuticals completes enrollment in the phase III clinical trials in Prostate cancer (Diagnosis) in USA and Canada (IV) (NCT03739684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top